INBS 1.60 Stock Price Intelligent Bio Solutions Inc.
Range: | 1.0-11.7 | Vol Avg: | 1771153 | Last Div: | 0 | Changes: | -0.09 |
Beta: | 4.72 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Wed Dec 23 2020 | Empoloyees: | 50 |
CUSIP: | | CIK: | 0001725430 | ISIN: | US36151G6008 | Country: | US |
CEO: | Mr. Harry Simeonidis | Website: | https://gbs.inc |
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.